ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

Kadcyla Extends Median PFS In Open-Label Phase III Trial

October 25, 2013

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

In Brief: Abeloff, Fisher Lead ASCO; Henney Replaces Antman On Govt. Relations; Ultmann Retires

May 31, 1991

Children, Parents Differ In Decisionmaking On Cancer Treatment, Survivor Study Finds

July 29, 2005

Univ. Of Pittsburgh Seeks Senior Prevention Trial Of Tamoxifin should Resume

June 17, 1994